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Abstract 
Major depression is a highly prevalent severe mood disorder that is treated 
with antidepressant medications1. The molecular targets of antidepressants require 
definition. We tested the role of the acid sphingomyelinase (Asm)/ceramide system 
as target for antidepressants. Therapeutic concentrations of the antidepressants, 
amitriptyline and fluoxetine, reduce Asm activity and ceramide concentrations in the 
hippocampus, increase neuronal proliferation, maturation, and survival, and improve 
behavior in mouse models of stress-induced depression. Genetic Asm deficiency 
abrogates these effects of antidepressants. Mice overexpressing Asm, heterozygous 
for acid ceramidase, treated with blockers of ceramide metabolism, or directly 
injected with C16 ceramide in the hippocampus exhibit increased ceramide 
concentrations, decreased neuronal proliferation, maturation, and survival, and 
depression-like behavior even in the absence of stress. All these features are 
normalized by the decrease of ceramide levels via antidepressant-mediated inhibition 
of Asm. Lowering ceramide levels may thus be a central goal for the future 
development of novel antidepressants.  
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Major depression is a severe, chronic, and often life-threatening illness with a 
lifetime prevalence of more than 10%1. Key symptoms of depression include 
depressed mood, loss of interest and pleasure, feelings of worthlessness, weight 
loss, insomnia and at least 10% of patients commit suicide.  
Major depression may be triggered by psychological stress, inflammatory 
cytokines, and dysfunction of the hypothalamic-pituitary-adrenal axis, etc.1–4.  
The previously held monoamine hypothesis for the action of antidepressants 
has been questioned because the antidepressant effect of these drugs is not clearly 
associated with their monoaminergic effect; in fact, the antidepressant tianeptine is 
even a serotonin reuptake enhancer5. Furthermore, the direct effect on monoamines 
contrasts with the delay of antidepressant effects in patients. Recent concepts of the 
pathogenesis of major depression suggest a change of cellular plasticity 
predominantly in the hippocampus and a shift in the balance between neurogenic 
and antiapoptotic events that leads to neurodegeneration and hippocampal atrophy6–
9. Antidepressants increase neurogenesis and reverse hippocampal atrophy 
associated with major depression9.  
Here, we tested the role of the acid sphingomyelinase (EC 3.1.4.12, 
sphingomyelin phosphodiesterase, human protein: ASM, murine protein: Asm, gene 
symbol: Smpd1) and ceramide system as a target for antidepressants. Asm is 
ubiquitously expressed and releases ceramide from sphingomyelin, predominantly in 
lysosomes but also in secretory lysosomes and on the plasma membrane10–13. 
 
The antidepressants amitriptyline, a tricyclic drug, and fluoxetine, a selective 
serotonin reuptake inhibitor, inhibited ASM activity in cultured neurons at therapeutic 
plasma concentrations recommended for patients with major depression14 (Fig. 1a). 
Treatment of wild-type (WT) mice with amitriptyline or fluoxetine dose dependently 
reduced hippocampal Asm activity and protein levels (Fig. 1b,c; Supplementary Fig. 
1a,b,d, Supplementary note 1), a finding consistent with the induction of partial 
proteolysis of Asm by amitriptyline and fluoxetine15,16. Mice transgenic for Asm (t-
Asm) exhibited increased Asm activity and protein levels in the hippocampus, and 
amitriptyline and fluoxetine reduced Asm activity and protein levels (Fig. 1b; 
Supplementary Fig. 1a,c,d). Asm-deficient mice were used as specificity control 
(Supplementary Fig. 1a). 
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The reduction of Asm levels and activity by amitriptyline or fluoxetine 
translated into a dose-dependent reduction of ceramide in the hippocampus of WT 
and t-Asm mice, as determined by diacylglycerol (DAG) kinase assays (Fig. 1d), 
mass spectrometry (Supplementary Fig. 2a) and fluorescence microscopy (Fig. 1e; 
Supplementary Fig. 2b–e,h). In contrast, the antidepressants did not alter 
hippocampal ceramide levels in Asm-deficient mice (Fig. 1d; Supplementary Fig. 
2a–c,f,h).  Constitutive hippocampal ceramide concentrations were lower in Asm-
deficient mice, and were higher in t-Asm mice, compared with WT mice (Fig. 1d; 
Supplementary Fig. 2a–c).  
To induce higher constitutive hippocampal ceramide independent of Asm, we 
generated acid ceramidase (Ac)-heterozygous mice, which exhibited approximately 
50% loss of Ac activity (data not shown) and very high concentrations of ceramide in 
the hippocampus; these concentrations were reduced by antidepressants (Fig. 1d, 
Supplementary Fig. 2a–c,g,h).  
Because major depression has been linked to stress1, we tested the effects of 
corticosterone, a well-established stress inducer (Supplementary note 2) on Asm 
and ceramide.  Corticosterone did not affect Asm activity or expression or ceramide 
levels (Fig. 1b,d; Supplementary Fig. 2a,i–n). 
 
Next, we determined whether inhibition of Asm mediates effects of 
amitriptyline and fluoxetine on neurogenesis, neuronal maturation and survival. 
Neurogenesis, neuronal maturation, and neuronal survival were lower in t-Asm and 
Ac-heterozygous mice than in WT mice, but were higher in Asm-deficient mice than 
in WT mice even in the absence of any treatment (Fig. 2a–c, Supplementary Figs. 
3a–d). Amitriptyline and fluoxetine increased neurogenesis, neuronal maturation, and 
survival in the hippocampus of stressed or non-stressed WT, t-Asm, and Ac-
heterozygous mice, but not in Asm-deficient mice (Fig. 2a–c, Supplementary Fig. 
3a). Controls show that hippocampal structural synaptic parameters and 
electrophysiological properties of hippocampal neurons did not differ between WT, 
Asm-deficient and t-Asm mice or cells, respectively (Supplementary Fig. 4a–d). 
Ceramide reduced Akt phosphorylation at serine 473, which was increased by 
antidepressants (Fig. 2d). C16 ceramide also inhibited proliferation of PC12 cells, an 
effect that was abrogated by expression of the constitutively-active T308DS473DAkt1 
mutant of Akt1 (Supplementary Fig. 5).  
Gulbins et al.: Acid sphingomyelinase and antidepressant drugs 
5 
 
The hypothesis that the Asm/ceramide system plays a role in the effect of 
antidepressants was confirmed by the abrogation of the previously-described effect 
of fluoxetine on egg laying17,18, which was abrogated in ams-1-deficient C. elegans 
(Fig. 2e). 5-HT still induced egg laying in asm-1-deficient worms and deletion of Mod-
5, the only serotonin transporter expressed in C. elegans, did not alter the effects of 
fluoxetine indicating that the 5-HT system is independent or at least partially 
downstream of asm-1 (Fig. 2e; Supplementary Figs. 6,7a,b).  
 
To further substantiate the role of the Asm/ceramide system as a target for 
antidepressants, we tested whether fendiline, a functional inhibitor of ASM16, that has 
not been reported to be an antidepressant, also acts as antidepressant. Fendiline 
reduced Asm activity and reduced ceramide concentrations in the hippocampus in 
WT and t-Asm (Fig. 2f; Supplementary Fig. 8a, Supplementary note 3). This 
resulted in increased neurogenesis, neuronal maturation and survival in WT, but not 
Asm-deficient mice, very similar to amitriptyline and fluoxetine (Fig. 2g; 
Supplementary Fig. 8b-d, Supplementary note 3). 
 
To further investigate the role of Asm in major depression, we determined 
whether ceramide determines the effects of amitriptyline, fluoxetine and fendiline on 
mouse behavior.  
Increased ceramide levels in the hippocampus of t-Asm mice and Ac-
heterozygous mice were associated with depression-like behavior (Fig. 3a–f; 
Supplementary Fig. 9). Treatment with antidepressants or fendiline normalized this 
endogenous stress-like state. Vice versa, Asm-deficient mice showed constitutively 
reduced stress behavior and, importantly, antidepressants or fendiline had no effect 
on Asm-deficient mice. Corticosterone application resulted in severe depressive-like 
behavior in all mouse types (Fig. 3a–f; Supplementary Fig. 9). Treatment with 
antidepressants or fendiline attenuated the corticosterone-induced depressive-like 
behavior in WT, t-Asm, and Ac-heterozygous mice, respectively, but had no effect on 
corticosterone-induced depressive-like behavior in Asm-deficient mice. These 
findings indicate that several behavioral effects of antidepressants depend on the 
presence of Asm and are mediated by a reduction of ceramide concentrations.  
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To further address the role of ceramide versus Asm in major depression, we 
increased ceramide in the hippocampus independent of Asm and Ac by administering 
the glycosyltransferase inhibitor DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-
propanol (PDMP), which prevents glycosylation of ceramide and has been shown to 
increase ceramide concentrations in gerbil hippocampus and cells19,20. PDMP 
treatment doubled ceramide concentrations, decreased neurogenesis and neuronal 
maturation in the hippocampus and induced depression-like symptoms in WT and 
Asm-deficient mice (Fig. 4a,b; Supplementary Fig. 10a–g). These alterations were 
corrected in WT mice by treatment with amitriptyline or fluoxetine, while the 
antidepressants had no effects in Asm-deficient mice treated with PDMP (Fig. 4a,b; 
Supplementary Fig. 10a–g).  
Further, reduction of ceramide in Ac-heterozygous mice by reduction of gene 
dosis of Asm normalized neurogenesis, maturation and depression-like behavior 
(Fig. 4a,b; Supplementary Fig. 10a–g).    
Finally, we injected C16 ceramide directly into the hippocampus of WT mice, 
which induced depression-like symptoms, while solvent controls were without effect 
(Fig. 4c; Supplementary Fig. 10h).  
 
To test the role of the Asm/ceramide system for the effects of antidepressants in 
a different stress model, we used the chronic unpredictable stress model. Chronic 
unpredictable stress increased ceramide concentrations ~2-fold in the hippocampus 
of both WT and Asm-deficient mice and concomitantly reduced neurogenesis and 
maturation (Fig. 4d,e), events that were normalized by antidepressants in WT mice, 
but not in Asm-deficient mice.  
 
Major depression is a common, complex, likely multifactorial psychiatric disorder. 
Here we propose a novel mode of action for antidepressants (Supplementary Fig. 
11): The complex balance between positive and negative stimuli in the hippocampus 
determines development of major depression. Ceramide acts as a negative regulator 
in the multifactorial pathogenesis of major depression. Inhibiting Asm activity reduces 
hippocampal ceramide concentrations and, thus, reduces the sum of the negative 
stimuli, thereby permitting normalization of behavior, neurogenesis, neuronal 
maturation, and neuronal survival.  
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Ceramide may regulate neurogenesis via several pathways: Ceramide 
controls activity of Akt shown to be important for neuronal proliferation21. Ceramide 
has been also shown to regulate the formation of reactive oxygen species via 
activation of NADPH oxidases22, to mediate the effects of the cytokines interleukin 
(IL)-1β and tumor necrosis factor (TNF)-α23–25 and to regulate stress-activated 
kinases26 and calcium release27. Thus, ceramide may coordinate negative effects on 
hippocampal neurons by Akt inhibition and assembling of molecules involved in 
oxidative stress, proinflammatory receptors and stress-signaling. Antidepressants 
counteract these events by reducing ceramide levels. This view is consistent with the 
finding that patients with major depression experience a wide range of abnormalities 
in organs such as heart, bone, and blood, in which oxidative stress, proinflammatory 
cytokines and sphingolipid levels are elevated28–32. These pathologic conditions 
might be explained by the increased ceramide concentration in major depression, not 
only in hippocampal neurons but also in other cells33.  
We therefore propose that ASM is an important target of antidepressant drugs 
in the hippocampus. We suggest that cellular ceramide concentrations may be a 
novel intermediate phenotype controlling hippocampal functions, including 
neurogenesis and neuronal networks that determine behavior.  
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Methods 
Mice and treatments: Asm-deficient mice (Smpd1-/-) show age-dependent 
accumulation of sphingomyelin and development of Niemann-Pick syndrome A or B, 
depending on the residual activity of ASM34. To avoid sphingomyelin accumulation, 
we used only Smpd1-/- mice with a maximum age of 12 weeks35. We observed no 
increase in cell death in the hippocampus of these mice (not shown). In Asm 
transgenic mice, the murine Smpd1 cDNA was expressed under the control of the 
ubiquitous CMV immediate-early enhancer/chicken β-actin promoter fusion promoter. 
A loxP-flanked STOP cassette was included between the promoter and the 
transgene so that the expression could be conditionally regulated by the action of Cre 
recombinase. The conditional transgene was introduced into the deleted Hprt gene 
locus of E14 embryonic stem cells. The transgenic mice were generated and back-
crossed for at least 5 generations to C57BL/6 mice. The transgene was constitutively 
expressed by crossing these mice with mice expressing Cre recombinase under the 
control of an E2A promoter36. For acid ceramidase 1 (Asah1)-heterozygous mice, the 
exon/intron organization of the gene was established on the basis of the Asah1 
cDNA sequence NM_019734. A targeting vector containing regions homologous to 
genomic Asah1 sequences was constructed. It included homology regions in the 
C57BL/6J genetic background, a long homology region of 5.8 kb and a short 
homology region of 1.7 kb; two loxP sites flanking Asah1 exon 1; a neomycin gene 
flanked by flippase recognition target sites for positive selection; and a diphtheria 
toxin A negative-selection marker to reduce the isolation of non-homologous 
recombined embryonic stem (ES) cell clones and to enhance the isolation of ES cell 
clones harboring the distal loxP site. This targeting vector was inserted into C57BL/6 
embryonic stem cells by homologous recombination. Offspring were crossed with 
E2A-Cre mice to generate mice heterozygous for Ac. 
Amitriptyline (100, 140, 180, or 220 mg L-1), fluoxetine (40, 80, 120 or 160 mg L-1), or 
fendiline (17, 33, 67.5, or 135 mg L-1) were administered for 35 days to mice via their 
drinking water. Drugs were dissolved in water, which was changed every 48 h. BrdU 
was injected at a dose of 75 mg kg-1 4 times (every 2 h) either 1 day or 21 to 28 days 
before the mice were sacrificed. Corticosterone was administered at 0.25 mg mL-1 in 
the drinking water for 28 days. If amitriptyline, fluoxetine, and corticosterone were 
administered together, the corticosterone treatment was initiated 7 days after the 
initiation of antidepressant treatment. 
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In the chronic unpredictable stress model the mice were challenged with 
unpredictable environmental stress for 5 weeks, i.e shift of the day-light cycle (for 
light/dark successions of 30 min every 24 h once a week), reversal of the light/dark 
cycle once a week, 3 h of 45 ° tilting of the cage twice a week, water deprivation for 
14 h once a week, predator sounds (15 min) three times a week. We used male and 
female mice. All studies were performed in accordance with animal permissions of 
the Regierungspraesidium Düsseldorf, Tübingen and the Regierung von 
Mittelfranken. 
Plasma levels of antidepressant drugs: Plasma levels of amitriptyline were 
measured by high-performance liquid chromatography; those of fluoxetine and 
fendiline by liquid chromatography tandem mass spectrometry.   
Pharmacological inhibition of ASM activity in vitro: Human brain neuroglioma H4 
cells (Promochem, Wesel, Germany) were cultured in DMEM with 10% fetal bovine 
serum and 4 mM glutamine at 37 °C, 8.5% CO2. H4 cells were grown to a confluence 
of 80% to 90%, incubated with amitriptyline, fluoxetine or fendiline at final 
concentrations from 0.1 to 10 µM for 24 h, washed and ASM activity was determined 
in whole-cell lysates11,16.  
Asm activity in mouse hippocampus: The hippocampal area was removed, shock 
frozen, and lysed in 250 mM sodium acetate (pH 5.0), 1% NP40, and 1.3 mM EDTA 
for 15 min. The tissues were then homogenized by two rounds of sonication for 10 s 
each with a tip sonicator. Aliquots of the lysates were diluted to 250 mM sodium 
acetate (pH 5.0), 0.1% NP40, and 1.3 mM EDTA; incubated with 50 nCi per sample 
[14C]sphingomyelin for 30 min at 37 °C; and processed as above.  
Measurement of ceramide by DAG kinase method: The hippocampal area was 
removed, homogenized in 200 µL H2O by tip sonication, and extracted in 
CHCl3:CH3OH:1N HCl (100:100:1, v/v/v). The lower phase was collected, dried, 
resuspended in 20 µL of a detergent solution (7.5% [w/v] n-octyl glucopyranoside, 5 
mM cardiolipin in 1 mM diethylenetriaminepentaacetic acid [DTPA]), and sonicated 
for 10 min. The kinase reaction was started by the addition of 70 µL of a reaction 
mixture containing 10 µL diacylglycerol (DAG) kinase (GE Healthcare Europe, 
Munich, Germany), 0.1 M imidazole/HCl (pH 6.6), 0.2 mM DTPA (pH 6.6), 70 mM 
NaCl, 17 mM MgCl2, 1.4 mM ethylene glycol tetraacetic acid, 2 mM dithiothreitol, 1 
µM adenosine triphosphate (ATP), and 5 µCi [32P]γATP. The kinase reaction was 
performed for 30 min at room temperature and terminated by the addition of 1 mL 
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CHCl3:CH3OH:1N HCl (100:100:1, v/v/v), 170 µL buffered saline solution (135 mM 
NaCl, 1.5 mM CaCl2, 0.5 mM MgCl2, 5.6 mM glucose, 10 mM HEPES [pH 7.2]), and 
30 µL of a 100 mM EDTA solution. The lower phase was collected, dried, and 
separated on Silica G60 thin-layer chromatography (TLC) plates with 
chloroform/acetone/methanol/acetic acid/H2O (50:20:15:10:5, v/v/v/v/v). The TLC 
plates were exposed to radiography films, the spots were removed from the plates, 
and the incorporation of [32P] into ceramide was measured by liquid scintillation 
counting. Ceramide amounts were determined by comparison with a standard curve 
using C16 to C24 ceramides as substrates. 
LC-MS analysis: The hippocampal area was removed and homogenized in 1 mL of 
methanol by tip sonication. Ceramides were extracted, 20 pmol of C17 ceramide in 
methanol were added as an internal standard, followed by the addition of 1 mL each 
of chloroform, distilled water, and methanol. After 2 min of intensive stirring, 1 mL 
chloroform was added. The sample was stirred again for 2 min, and 1 mL of distilled 
water was added. The lower organic phase was collected, and the aqueous phase 
was extracted twice with 1 mL of chloroform. The combined organic phases were 
dried, lipids were resolved in 200 µL of methanol and analysed by rapid-resolution 
liquid chromatography mass spectrometry (LC-MS) using an Agilent 1200 Series 
binary pump, a degasser, and an autosampler (Agilent Technologies, Böblingen, 
Germany). A quadrupole time-of flight 6530 mass spectrometer equipped with Jet-
Stream Technology operating in the positive electrospray ionization mode was used 
for detection (Agilent Technologies). High-purity nitrogen for the mass spectrometer 
was produced by a nitrogen generator (Parker Balston, Maidstone, UK). 
Chromatographic separations were obtained with a ZORBAX Eclipse XDB-C18 (C18, 
4.6×50 mm, 1.8 µm particle size, 80 Å pore size; Agilent Technologies). The injection 
volume per sample was 10 µL. An isocratic solvent system consisting of 
acetonitrile/2-propanol 3:2 (v/v) with 1% formic acid and a flow rate of 1 mL min-1 
over 15 min was used. For mass spectrometric measurements, the following ion 
source conditions and gas settings for positive LC-MS/MS were adjusted: sheath gas 
temperature, 400 °C; sheath gas flow, 9 L min-1; nebulizer pressure, 30 psig; drying 
gas temperature, 350 °C; drying gas flow, 8 L min-1; capillary voltage, 2000 V; 
fragmentor voltage, 355 V; nozzle voltage, 2000 V. All ceramides gave the same 
fragment ion of m/z 264.27 at various retention times, depending on their chain 
length. Counting was performed with Mass Hunter Software. Calibration curves of 
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reference ceramides were performed from 1 pmol to 100 pmol and were constructed 
by linear fitting using the least-squares linear regression calculation. The resulting 
slope of the calibration curve was used to calculate the concentration of the 
respective analyte in the samples.  
Immunohistochemical analysis of Asm and ceramide: Mice were euthanized and 
perfused via the left heart for 2 min with 0.9% NaCl and for 15 min with 4% 
paraformaldehyde (PFA) buffered in PBS (pH 7.3). Brains were removed, fixed for an 
additional 36 h in 4% buffered PFA in PBS, and embedded in paraffin. The 
hippocampus was serially sectioned. The sections were dewaxed, incubated for 30 
min with pepsin (Digest All, Invitrogen, Darmstadt, Germany) at 37 °C, washed, and 
blocked for 10 min with PBS, 0.05% Tween 20, and 5% fetal calf serum (FCS). They 
were then immunostained for 45 min with polyclonal rabbit antibodies against murine 
Asm, obtained by immunization with a glutathione-S-transferase (GST) fusion protein 
(aa 518–564) of mouse Asm. The results were confirmed by staining with a 
monoclonal antibody against Asm. Ceramide was detected with a ceramide-specific 
antibody (clone S58-9, Glycobiotech, Kükels, Germany). All antibodies were diluted 
1:100 in HEPES/Saline (H/S; 132 mM NaCl, 20 mM HEPES [pH 7.4], 5 mM KCl, 1 mM 
CaCl2, 0.7 mM MgCl2, 0.8 mM MgSO4) + 1% FCS, washed 3 times in PBS + 0.05% 
Tween 20, incubated for 45 min with Cy3-coupled donkey anti-rabbit IgG or anti-
mouse IgM F(ab)2 fragments (Jackson ImmunoResearch, Newmarket, UK), washed 
again three times in PBS + 0.05% Tween 20 and once in PBS, and embedded in 
Mowiol. Immunofluorescence was measured with the Leica TCS SL software 
program, version 2.61 (Leica, Mannheim, Germany).  
Immunohistochemical BrdU, doublecortin, NeuN, and GFAP stainings: For BrdU 
staining, mice were injected with BrdU, sacrificed and brains were prepared as 
above. Paraffin-embedded sections were dewaxed, treated for 20 min with pepsin at 
37 °C, washed, incubated for 2 h with 50% formamide in 300 mM NaCl and 30 mM 
saline sodium citrate (pH 7.0) at 65 °C, and washed twice in saline sodium citrate 
buffer. The DNA was denatured for 30 min at 37 °C with 2 M HCl, washed, 
neutralized for 10 min with 0.1 M borate buffer (pH 8.5), washed, and blocked with 
0.05% Tween 20 and 5% FCS in PBS (pH 7.4). The samples were then stained with 
5 µg mL-1 BrdU-specific antibody (Roche, Mannheim, Germany) for 45 min at 22 °C, 
washed, and stained with Cy3-coupled F(ab)2 anti-mouse IgG (Jackson 
ImmunoResearch). Serial sections were counted by a “blinded” investigator.  
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For doublecortin staining, the samples were demasked in citrate buffer after 
rehydration, incubated in a microwave for 15 min at 650 W, washed in PBS, blocked 
in blocking solution (Candor Biosciences, Wangen, Germany), stained with 
antibodies against doublecortin (1:100, Abcam, Cambridge, UK) for 45 min at 22 °C, 
washed 3 times in PBS/0.05% Tween 20, stained with Cy3-anti-rabbit F(ab)2 
fragments, washed again, and embedded in Mowiol.  
Anti-BrdU and GFAP doublestainings: After staining with BrdU-specific 
antibodies, the samples were incubated with antibodies for GFAP (1:1000, Dako, 
Eching, Germany) for 45 min at 22 °C, washed 3 times in PBS/0.05% Tween 20 and 
once in PBS, stained with FITC anti-rabbit IgG F(ab)2 fragments for 45 min at 22 °C, 
washed again, and embedded in Mowiol.  
For BrdU and NeuN doublestainings, samples were processed as above for 
BrdU, incubated with BrdU-specific antibodies for 45 min at 22 °C, washed 3 times in 
PBS/0.05% Tween 20 and once in PBS, fixed for 15 min in 2% PFA/PBS (pH 7.3), 
washed 4 times with PBS, demasked in citrate buffer for 15 min in a microwave at 
650 W, washed, blocked with PBS/0.05% Tween/5% FCS for 15 min, washed, 
incubated with antibodies against NeuN (1:100; Millipore, Schwalbach, Germany) for 
45 min at 22 °C, washed 3 times in PBS/0.05% Tween 20 and once in PBS, stained 
with Cy3-anti-rat IgG F(ab)2 fragments (1:100) and FITC-anti-mouse IgG F(ab)2 
fragments (1:500) for 45 min at 22 °C, washed, and embedded.  
Neurogenesis and neuronal survival were determined by BrdU labeling 1 day 
or 21 to 28 days before the mice were sacrificed. Maturation was analyzed by 
doublecortin staining. Every tenth section of serial sections of the hippocampus was 
counted. 
Western blots: The hippocampal area was removed, immediately shock frozen, and 
homogenized with a tip sonicator in 100 µl 0.1% SDS, 25 mM HEPES, 0.5% 
deoxycholate, 0.1% Triton X-100, 10 mM EDTA, 10 mM sodium pyrophosphate, 10 
mM sodium fluoride, 125 mM NaCl, and 10 µg g-1 aprotinin/leupeptin. Samples were 
lysed for 5 min at 4 °C and centrifuged at 14,000 rpm for 5 min at 4 °C, after which 20 
µL 5x SDS-Laemmli buffer was added. Proteins were separated by 8.5% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), incubated with 
either an antibody specific for phospho-Ser-473-Akt or for Akt (both diluted 1:1,000, 
Cell Signalling, Frankfurt, Germany) for 1 h at 22 °C, washed, and developed with 
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alkaline phosphatase-coupled secondary antibodies with the Tropix 
chemoluminescence system.  
Behavioral studies: Behavioral testing was performed between 3:00 P.M. and 6:00 
P.M. If appropriate, animals were video tracked by a camera (Noldus-Systems, 
Worpswede, Germany). All tests were performed on separate days. Experiments 
were performed with diffuse indirect room light. Novelty-suppressed feeding was 
measured as the length of time during which the mice explored a new environment 
before they began eating after a fasting period of 24 h. For the forced swim test, 
mice were placed in a cylinder filled with water (21–23 °C) for 15 min. After 24 h the 
mice were again placed in a water-filled cylinder for 6 min, and the time of mobility 
during the last 4 min of the second trial was recorded. Mice were judged immobile 
when they moved only to keep their heads above water. A quadratic open-field arena 
was used with sides 50 cm long, a white plastic floor, and sidewalls 30 cm high. Each 
animal was released near the wall and observed for 30 min. The open field was 
defined as 10 cm away from the wall. The light/dark box test consisted of a dark 
and safe compartment and a brightly illuminated, open, and thus aversive area. An 
aperture of 5×5 cm with rounded-down corners led from the light area to the dark 
box. Each mouse was released in the dark compartment and observed for 5 min. 
Coat state was scored on the head, neck, back, and ventrum with either a zero for a 
normally groomed coat or a 1 for an unkempt coat at each site. The elevated plus 
maze was performed with a maze consisting of two side-shielded arms and two open 
arms (height, 40 cm). Mice were placed into the central area, and behaviour was 
tested for 5 min. In the splash test, 200 µL of a 10% sucrose solution was spotted 
onto the mouse’s snout, and the latency to begin grooming and the grooming 
frequency over 5 min were measured. Control experiments showed that the different 
genotypes did not differ in their locomotion. 
Egg-Laying Assay: asm-1(kk-1) worms and wild type C. elegans Bristol strain (N2) 
(from Caenorhabditis Genetics Center, University of Minnesota, Minneapolis, USA) 
were cultured at 20 °C and fed with Escherichia coli OP50 as a food source. Egg 
laying was counted from young adults that were picked as L4 larvae from OP50 
plates and transferred to fresh bacteria plates before the assay. After development 
for 20 h at 20 °C, worms from these plates were then transferred individually to 96-
well microplates containing 50 µL M9 buffer (20 mM KH2PO4, 40 mM Na2HPO4, 80 
mM NaCl, 1 mM MgSO4) per well with or without 1 mM fluoxetine or 12.5 mM 5-
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hydroxytryptamine. The number of eggs released was scored after 90 min at room 
temperature. Each assay contained 6 to 8 worms for each experimental group. 
Hippocampal ceramide injection and behavior: Adult male C57BL/6J mice 
(Charles River, Germany) were deeply anaesthetized with 1 g kg-1 ketamine and 76 
mg kg-1 medetomidine hydrochloride i.p. and 100 mg kg-1 metamizol s.c. The animal 
was placed in a Kopf stereotaxic frame. Two injection cannulas (Microbiotech/se AB, 
Stockholm, Sweden) were aimed at the dorsal hippocampus (AP -2.0; ML ± 1.5; DV -
2.3 mm) using coordinates relative to bregma, and fixed in place using two anchor 
screws (stainless steel, d=1.4 mm) and dental cement. Animals were kept warm and 
allowed to recover from anaesthesia. Animals were then returned to their home cage 
for single housing and monitored daily, allowing at least 4 days for complete 
recovery. All animals received seven bilateral injections with either 2 µM C16 
ceramide (Cayman, Ann Arbor, USA) or ghost micelles. C16 ceramide solution was 
prepared in 2% octyl ß-D-glucopyranoside and sonicated for 10 min prior to use. The 
ceramide test dose was determined after a dose-response test (2–200 µM). In that, 2 
µM ceramide had no acute adverse effects on behavior. All injections were spaced 
48 h apart. The injection volume was 0.2 µL per side, delivered at a flow rate of 0.1 
µL min-1. After injection, cannulas were left in place for 1 min to allow for diffusion. 
After the 7th injection, coat state was scored and one day later, novelty-suppressed 
feeding was tested as described above. Then animals received two more ceramide 
injections spaced 48 h apart before sucrose preference was tested on four 
consecutive days. Each animal received two bottles constantly available, one filled 
with a 2% sucrose solution and one with water. Percent preference of sucrose vs. 
water was measured every day. After the behavioral tests, animals were sacrificed by 
cervical dislocation, and brains were removed for verification of probe localization37. 
Statistical analysis: Data were examined with analysis of variance (ANOVA) and 
post hoc tests. A P value of 0.05 or less (two-tailed) was considered indicative of 
statistical significance.  
 
 
Gulbins et al.: Acid sphingomyelinase and antidepressant drugs 
16 
REFERENCES 
 
1. Belmaker, R.H. & Agam, G. Major depressive disorder. N. Engl. J. Med. 358, 
55–68 (2008). 
2. Howren, M.B., Lamkin, D.M. & Suls, J. Associations of depression with C-
reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71, 171–
186 (2009). 
3. Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol. 
Psychiatry 67, 446–-457 (2010). 
4. Walker, J.R. et al. Psychiatric disorders in patients with immune-mediated 
inflammatory diseases: prevalence, association with disease activity, and 
overall patient well-being. J. Rheumatol. S88, 31–35 (2011).  
5. Brink, C.B., Harvey, B.H. & Brand, L. Tianeptine: a novel atypical 
antidepressant that may provide new insights into the biomolecular basis of 
depression. Rec. Pat. CNS Drug Discov. 1, 29–41 (2006). 
6. Santarelli, L. et al. Requirement of hippocampal neurogenesis for the 
behavioral effects of antidepressants. Science 301, 805–809 (2003). 
7. Koo, J.W. & Duman, R.S. IL-1beta is an essential mediator of the 
antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. U. S. A. 
105, 751–756 (2008). 
8. David, D.J. et al. Neurogenesis-dependent and -independent effects of 
fluoxetine in an animal model of anxiety/depression. Neuron 62, 479–493 
(2009). 
9. Warner-Schmidt, J.L. & Duman, R.S. Hippocampal neurogenesis: opposing 
effects of stress and antidepressant treatment. Hippocampus 16, 239–249 
(2006). 
10. Gulbins, E. & Kolesnick, R. Raft ceramide in molecular medicine. Oncogene 
22:7070–7077 (2003). 
11. Grassmé, H. et al. CD95 signaling via ceramide-rich membrane rafts. J. Biol. 
Chem. 276, 20589–20596 (2001). 
12. Perrotta, C. et al. Syntaxin 4 is required for acid sphingomyelinase activity and 
apoptotic function. J. Biol. Chem. 285, 40240–40251 (2010). 
13. Grassmé, H. et al. Host defense against Pseudomonas aeruginosa requires 
ceramide-rich membrane rafts. Nat. Med. 9, 322–330 (2003). 
Gulbins et al.: Acid sphingomyelinase and antidepressant drugs 
17 
14. Baumann, P. et al. The AGNP-TDM Expert Group Consensus Guidelines: 
focus on therapeutic monitoring of antidepressants. Dialogues Clin. Neurosci. 
7, 231–247 (2005). 
15. Kölzer, M., Werth, N. & Sandhoff, K. Interactions of acid sphingomyelinase 
and lipid bilayers in the presence of the tricyclic antidepressant desipramine. 
FEBS Lett. 559, 96–98 (2004) 
16. Kornhuber, J. et al. Identification of new functional inhibitors of acid 
sphingomyelinase using a structure-property-activity relation model. J. Med. 
Chem. 51, 219–237 (2008). 
17. Ranganathan, R., Sawin, E.R., Trent, C. & Horvitz, H.R. Mutations in the 
Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal 
serotonin-dependent and -independent activities of fluoxetine. J. Neurosci. 21, 
5871–5884 (2001). 
18. Dempsey, C.M., Mackenzie, S.M., Gargus, A., Blanco, G. & Sze, J.Y. 
Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT 
receptor signaling to modulate Caenorhabditis elegans egg-laying behavior. 
Genetics 169, 1425–1436 (2005). 
19. De Stefanis, D. et al. Increase in ceramide level alters the lysosomal targeting 
of cathepsin D prior to onset of apoptosis in HT-29 colon cancer cells. Biol. 
Chem. 383, 989–999 (2002). 
20. Hisaki, H. et al. In vivo influence of ceramide accumulation induced by 
treatment with a glucosylceramide synthase inhibitor on ischemic neuronal cell 
death. Brain. Res. 1018, 73–77 (2004). 
21. Peltier, J., O'Neill, A. & Schaffer, D.V. PI3K and CREB regulate adult neural 
hippocampal progenitor proliferation and differentiation. Dev. Neurobiol. 67, 
1348–1361 (2007).  
22. Zhang, Y., Li, X., Carpinteiro, A. & Gulbins, E. Acid sphingomyelinase 
amplifies redox signaling in Pseudomonas aeruginosa-induced macrophage 
apoptosis. J. Immunol. 181, 4247–4254 (2008). 
23. Mathias, S., Younes, A., Kan, C.C., Orlow, I., Joseph, C., & Kolesnick, R.N. 
Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a 
cell-free system by IL-1 beta. Science 259, 519–522 (1993). 
24. Wiegmann, K., Schütze, S., Machleidt, T., Witte, D. & Krönke, M. Functional 
dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor 
Gulbins et al.: Acid sphingomyelinase and antidepressant drugs 
18 
signaling. Cell 78, 1005–1015 (1994). 
25. Kim, M.Y., Linardic, C., Obeid, L. & Hannun, Y. Identification of sphingomyelin 
turnover as an effector mechanism for the action of tumor necrosis factor 
alpha and gamma-interferon. Specific role in cell differentiation. J. Biol. Chem. 
266, 484–489 (1991). 
26. Brenner, B., Koppenhoefer, U., Weinstock, C., Linderkamp, O., Lang, F. & 
Gulbins, E. Fas- or ceramide-induced apoptosis is mediated by a Rac1-
regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J. 
Biol. Chem. 272, 22173–22181 (1997). 
27. Lepple-Wienhues, A. et al. Stimulation of CD95 (Fas) blocks T lymphocyte 
calcium channels through sphingomyelinase and sphingolipids. Proc. Natl. 
Acad. Sci. U. S. A. 96, 13795–13800 (1999). 
28. Müller, N. COX-2 inhibitors as antidepressants and antipsychotics: clinical 
evidence. Curr. Opin. Investig. Drugs 11, 31–42 (2010). 
29. Walker, J.R. et al. Psychiatric disorders in patients with immune-mediated 
inflammatory diseases: prevalence, association with disease activity, and 
overall patient well-being. J. Rheumatol. S88, 31–35 (2011).  
30. Rudisch, B. & Nemeroff, C.B. Epidemiology of comorbid coronary artery 
disease and depression. Biol. Psychiatry 54, 227–240 (2003).  
31. Kojima, M. et al. Depression, inflammation, and pain in patients with 
rheumatoid arthritis. Arthritis Rheum. 61, 1018–1024 (2009).  
32. Tabas, I. Sphingolipids and atherosclerosis: a mechanistic connection? A 
therapeutic opportunity? Circulation 110, 3400–3401 (2004). 
33. Kornhuber J et al. High activity of acid sphingomyelinase in major depression. 
J. Neural. Transm. 112, 1583–1590 (2005). 
34. Horinouchi, K. et al. Acid sphingomyelinase deficient mice: a model of types A 
and B Niemann-Pick disease. Nat. Genet. 10, 288–293 (1995). 
35. Lozano, J. et al. Niemann-Pick Disease versus acid sphingomyelinase 
deficiency. Cell Death Differ. 8, 100–103 (2001). 
36. Lakso, M. et al. Efficient in vivo manipulation of mouse genomic sequences at 
the zygote stage. Proc. Natl. Acad. Sci. U. S. A. 93, 5860–5865 (1996) 
37. Amato, D., Müller, C.P., & Badiani, A. Increased drinking after intra-striatal 
injection of the dopamine D2/D3 receptor agonist quinpirole in the rat. 
Psychopharmacology 223, 457–463 (2012). 
Gulbins et al.: Acid sphingomyelinase and antidepressant drugs 
19 
FIGURE LEGENDS 
 
 
Fig. 1: Amitriptyline and fluoxetine reduce hippocampal ceramide 
concentrations by inhibiting acid sphingomyelinase activity 
(a) Acid sphingomyelinase (human: ASM) activity in human H4 neural cells at 
different concentrations of amitriptyline or fluoxetine. Therapeutic plasma 
concentrations of the antidepressants are indicated. Means ± s.d. of three 
independent experiments. Absolute values of ASM activity at 0.1 µM amitriptyline or 
fluoxetine were 6.08 ± 2.17 or 6.67 ± 3.07 nmol mg protein-1 h-1, respectively. (b) 
Acid sphinfomyelinase (mouse: Asm) activity in the hippocampus of WT and Asm-
transgenic (t-Asm) mice is dose-dependently inhibited by amitriptyline (Ami.) and 
fluoxetine (Fluox.). Means ± s.d. from WT mice (n=6–12 per group) and t-Asm mice 
(n=6–8 per group). Doses of amitriptyline and fluoxetine in mg L-1. *, P < 0.05 
compared to untreated WT mice; Δ, P < 0.05 compared to untreated t-Asm mice, 
ANOVA. (c) Immunostainings of hippocampal sections using Cy3-coupled antibodies 
against Asm show reduced expression of Asm in the dentate gyrus (upper row) and 
CA3 region (lower row) of amitriptyline or fluoxetine treated compared to untreated 
mice. Representative results from 9–12 mice per group; magnification 200×. (d) 
Ceramide levels in unstressed or corticosterone (corticost.)-stressed mice that were 
treated with amitriptyline and fluoxetine or left untreated. Doses of amitriptyline and 
fluoxetine in mg L-1. Means ± s.d. (180 mg L-1 amitripytline and 80 mg L-1 fluoxetine: 
WT, Asm-deficient: n=12, t-Asm: n=9, all other doses: n=5; Ac-heterozygous mice: 
n=4.). *, P < 0.05 compared to untreated WT mice; Δ, P < 0.05 compared to the 
corresponding untreated mice; ANOVA. (e) Immunostainings of hippocampal 
sections with Cy3-coupled antibodies against ceramide show reduction of ceramide 
in the dentate gyrus (upper row) and CA3 regions (lower row) after treatment of WT 
mice with amitriptyline or fluoxetine. Representative figures from 12 mice each.  
 
Fig. 2: The acid sphingomyelinase/ceramide system is required for the 
neurobiological effects of antidepressants 
Neurogenesis (a), neuronal maturation (b), and neuronal survival (c) in the 
hippocampus of unstressed or corticosterone-stressed mice that were treated with 
amitriptyline or fluoxetine. Asm-deficient mice did not respond to the antidepressants 
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(a–c). Asm-deficient mice exhibit a constitutive increase in neurogenesis, neuronal 
maturation, and neuronal survival rates, while these parameters are decreased in t-
Asm and Ac-heterozygous mice (a–c). Mean ± s.d. (n=12 WT, t-Asm, and Asm-
deficient mice in a and n=6 each in b, c; n=5 Ac-heterozygous mice). *, P < 0.05 
compared to untreated WT mice; Δ, P < 0.05 compared to corresponding mice, 
ANOVA). (d) Western blots showing constitutive and antidepressants-induced 
phosphorylation of Ser 473 of Akt. Aliquots of the samples were blotted with 
antibodies against Akt (lower blots). The blots are representative of results from 4–6 
mice/group. (e) Fluoxetine- and 5-Hydroxytryptamine (5-HT) induced egg laying in 
WT, asm-1 and mod-5 deficient C. elegans. Mean ± s.d. from 6–8 worms per group. 
*, P < 0.05 compared to untreated WT worms; Δ, P < 0.05 compared to untreated 
corresponding genotype; ANOVA. (f,g) Asm activity neurogenesis and neuronal 
survival in non-stressed and stressed mice treated with fendiline or left untreated. 
Mean ± s.d. from each 6 (f and neurogenesis) or 4 (survival) mice. *, P < 0.05 
compared to untreated WT mice; Δ, P < 0.05 compared to untreated Asm-deficient 
mice; ANOVA. 
 
Fig. 3: Behavioral effects of antidepressant drugs can be mediated by the 
inhibition of acid sphingomyelinase  
Novelty-suppressed feeding (a), coat (b), splash (c), open-field (d), light/dark box (e), 
and forced swim (f) tests in non-stressed and corticosterone-stressed mice treated 
with antidepressants, fendiline or left untreated. Mean ± s.d., number of mice per 
group in a from left to right: 41, 42, 19, 9, 12, 12, 12, 9, 33, 28, 14, 9, 12, 12, 12, 8, 
19, 14, 12, 10, 12, 12, 12, 10, otherwise WT, Asm-deficient, t-Asm mice: n=6, Ac-
heterozygous mice: n=5. *, P < 0.05 compared to untreated WT mice; Δ, P < 0.05 
compared to untreated control of each genotype, ANOVA.  
 
Fig. 4: Hippocampal ceramide has a critical role in depression-like phenotypes 
Ceramide levels (a) and neurogenesis (b) in unstressed or corticosterone-stressed 
mice treated with PDMP and/or amitriptyline or fluoxetine. Heterozygosity of the Asm 
in Ac-heterozygous mice reduces ceramide levels and improves neurogenesis 
compared to Ac-heterozygous mice. Doses of amitriptyline and fluoxetine in mg L-1. 
Mean ± s.d. from 5 mice each. *, P < 0.05 compared to untreated WT mice; Δ, P < 
0.05 compared to PDMP alone or corticosterone + PDMP as appropriate; #, P < 0.05 
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compared to corticosterone alone as appropriate; ANOVA. (c) Injection of C16 
ceramide (Cer) into the hippocampus results in depression-like symptoms as 
assessed by reduced sucrose preference and prolonged latency to feed. Mean ± 
s.e.m. from 5 mice for vehicle treated control (Veh) and 8 mice for Cer *, P < 0.05, t-
test. (d,e) Hippocampal ceramide, neurogenesis and maturation in WT and Asm-
deficient mice subjected to chronic unpredictable stress (CUS) and treated with 
amitriptyline or fluoxetine or left untreated. Mean ± s.d. from 5 mice each. *, P < 0.05 
compared to untreated WT mice; Δ, P < 0.05 compared to CUS-treated mice of each 
genotype, ANOVA. 
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